Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Gynecologic 1

Conditions

Carcinoma, Renal Cell 2Melanoma 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × peginterferon alfa-2b × Genitourinary × Clear all
NCT02089685 2022-09-13

MK-3475-029

Merck Sharp & Dohme LLC

Phase 1/2 Completed
295 enrolled 25 charts
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00522249 2016-03-17

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

The Methodist Hospital Research Institute

Phase 1/2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡